Arzneimittelforschung 2010; 60(3): 157-161
DOI: 10.1055/s-0031-1296265
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Bioequivalence study of two formulations of 100 mg capsule of itraconazole

Quantification by tandem mass spectrometry
Josélia Larger Manfio
1   BIOCINESE – Biopharmaceutical Studies Center, Toledo, PR, Brazil
Maurício Bedin dos Santos
1   BIOCINESE – Biopharmaceutical Studies Center, Toledo, PR, Brazil
Wagner Alex Jann Favreto
1   BIOCINESE – Biopharmaceutical Studies Center, Toledo, PR, Brazil
Anelise Weich
1   BIOCINESE – Biopharmaceutical Studies Center, Toledo, PR, Brazil
Ana Maria Pugens
1   BIOCINESE – Biopharmaceutical Studies Center, Toledo, PR, Brazil
Carmen Maria Donaduzzi
2   Prati, Donaduzzi & Cia Ltda, Toledo, PR, Brazil
› Institutsangaben
Weitere Informationen


02. Dezember 2011 (online)


The purpose of this study is to compare the bioavailability of two itraconazole (CAS 84625-61-6) capsule formulations. An open, randomized, two-period cross-over study with a 7-day washout interval was conduced in 32 healthy volunteers. The plasma samples were obtained up to 96 h after drug administration. A sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS)method was developed and validated for the determination of itraconazole in human plasma. Itraconazole and ketocona-zole (internal standard) were extracted from the plasma by liquid-liquid extraction using diethylether: dichloromethane(70 : 30) as extraction solvent and separated on a C8 analytical column (150 mm × 4.6 mm I.D.) maintained at 40 °C. The elution was performed by a constant flow rate of 1.2 mL/min and the mobile phase consisted of acetonitrile and acetic acid 0.1% (85 : 15 v/v). The mass spectrometer equipped with an electrospray source in positive mode, was set up in multiple reaction monitoring, to detect parent → product ion 705.0 →392.0 (itraconazole) and 531.0 → 81.70 (ketoconazole). The chromatographic separation was obtained within 3.5 min and was linear in the concentration range of 5 to 600 ng/mL. Bioequivalence between the products was determined by calculating 90% confidence intervals for the ratio of Cmax (95.02%–109.48%), AUC0–t (81.41% – 107.77%) and AUC0–∞(80.85% – 106.86%). These values for the test and reference products are within the 80–125% interval, proposed by FDA and EMEA. It was concluded that the proposed method was successfully applied to a pharmacokinetic study in healthy human volunteers, and results showed that the two itraconazole formulations are bioequivalent in their rate and extent of absorption.

  • Literature

  • 1 Martindale. The Extra Pharmacopoeia. 34rd ed. Reymonds JEF. editor London: The Pharmaceutical Press; 2005: 325
  • 2 Negroni R, Arechavala AI. Itraconazole: pharmacokinetics and indications. Arch Med Res. 1993; 24 (4) 387-93
  • 3 FDA/CDER Guidance for Industry Bioanalytical Method Validation. Rockville (MD): FDA; 2001
  • 4 FDA/CDER Guidance for Industry, Food-effect bioavailability and fed bioequivalence studies. Rockville (MD): FDA; 2002
  • 5 Yao M, Chen L, Srinivas NR. Quantitation of itraconazole inrat heparinized plasma by liquid chromatography-mass spectrometry. J Chromato gr B. 2001; 752: 9-16
  • 6 Carrier A, Parent J. Liquid chromatographic-mass spectrometric determination of itraconazole and its major metabolite, hydroxyitraconazole, in dog plasma. J Chromatogr B. 2000; 745: 413-20
  • 7 Srivatsan V, Dasgupta AK, Kale P, Datla RR, Soni D, Patel M et al. Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performanceliquid chromatography. J Chromatogr A. 2004; 1031: 307-13
  • 8 Wong JW, Nisar U, Yuen KH. Liquid chromatographymethod for the determination of plasma itraconazole and its hydroxyl metabolite in pharmacokinetic/bioavailability studies. J Chromatogr B. 2003; 798: 355-60
  • 9 Koks CHW, Sparidans RW, Lucassen G, Crommentuyn KML, Beijnen JH. Selective high-performance liquid chromatographic assay for itraconazole and hydroxy itraconazole in plasma from human immunodeficiency virus-infected patients. J Chromatogr B. 2002; 767: 103-10
  • 10 Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC et al. Food interaction and steady-state pharmacokinetics of itaconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993; 37: 778-84
  • 11 Barone JA, Moskovitz BL, Guarnieri J, Hassel AE, Colaizzi JL, Bierman RH et al. Enhance bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother. 1998; 42 (7) 1862-5
  • 12 Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai WJ. Reduced oral itraconazole bioavailability by antacidsuspension. Clin Pharm Ther. 2005; 30: 201-6
  • 13 Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharm. 1994; 46 (2) 147-50
  • 14 Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1998; 32 (9) 1310-3